UNCOMMON ADVERSE DRUG REACTION OF CISPLATIN-INDUCED OTOTOXICITY IN AN ONCOLOGY PATIENT: A CASE REPORT

Dr. Challa Srilekha* and Dr. Safi Almas

Background: Dose-dependent toxicities are associated with cisplatin, a widely used platinum-based chemotherapeutic agent. Among the adverse effects, ototoxicity is a major concern. Hearing loss is mainly sensorineural and often bilateral, severely affecting communication, social interaction, and quality of life. Early identification and intervention can prevent permanent auditory damage Case Presentation: We describe a patient who was on cisplatin-based chemotherapy and presented with progressive bilateral tinnitus and hearing impairment. Clinical and audiological evaluation revealed high-frequency sensorineural hearing loss, a typical presentation of cisplatin ototoxicity. Treatment consisted of drug discontinuation from temporary use of cisplatin, administration of corticosteroids and antioxidants, and regular audiological follow-up. Partial relief of symptoms and stabilization of hearing thresholds were observed. Conclusion: With cisplatin-induced ototoxicity still being a clinically relevant challenge in oncology practice, audiological testing at baseline and follow-up during chemotherapy would help with early identification. Early intervention, counseling of patients, and preventive measures should all be implemented to minimize the risk of permanent hearing impairment and better the prognosis of the patient.